Heartflow (NASDAQ:HTFL) Now Covered by Analysts at Canaccord Genuity Group

Key Points

• Analysts at Canaccord Genuity Group have initiated coverage of Heartflow (NASDAQ:HTFL) with a "buy" rating and a price target of $35.00, indicating an 11.11% potential upside.
• Heartflow's current stock price is $31.50, with 12-month high and low values of $36.68 and $26.56, respectively.
• The company has been recognized for its innovative use of AI in diagnosing coronary artery disease, with its platform assessing over 400,000 patients as of March 31, 2025.

Canaccord Genuity Group started coverage on shares of Heartflow (NASDAQ:HTFL - Free Report) in a research note released on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $35.00 target price on the stock.

Separately, Wall Street Zen raised shares of Heartflow to a "hold" rating in a research note on Saturday, August 16th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.80.

Heartflow Stock Down 8.8%

Shares of HTFL traded down $3.01 during mid-day trading on Tuesday, hitting $31.07. 442,043 shares of the company's stock were exchanged, compared to its average volume of 878,154. Heartflow has a 52 week low of $26.56 and a 52 week high of $36.68.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.